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GENETIC SCREENING FOR ABNOR-
MAL EMBRYOS
The Human Fertilisation and Embryology
Authority (HFEA), the body that regulates
in vitro fertilization (IVF) in the UK, has
agreed in principle to allow embryos to
be screened for an abnormal number of
chromosomes.  The technique called aneu-
ploidy can screen out embryos that are
aneuploid (contain more or less than 46
chromosomes).  Embryos that contain an
abnormal number of chromosomes usu-
ally result in a failure to implant in the
womb that can lead to miscarriage.  For
such reasons, HFEA contends that aneup-
loidy screening would be of particular ben-
efit to women who have suffered repeated
miscarriages or unsuccessful IVF.  Addi-
tionally, the screening would also likely
increase the success rate of IVF by elimi-
nating embryos that have little chance of
implanting in the womb.
A fertilization clinic in London and another
in Nottingham have applied for licenses
to conduct aneuploidy screening.  A
spokesman for HFEA stated that any such
license would be subject to satisfactory in-
spection of the intended laboratories; ap-
proval of clinic staff; the provision of de-
tailed technical and patient information;
and ongoing monitoring.  HFEA recog-
nizes that although the technique is used
in a number of fertilization clinics around
the world, it is still in its early stages of
utilization and needs to be overseen.
Paul Scriven, a principal scientist at Guys
and St. Thomass Hospitals NHS Trust in
London, said that with present aneuploidy
testing methods, it is too easy to misdi-
agnose a normal embryo as abnormal and
therefore not attempt to transfer it into the
womb.  Other opponents of the screening
are concerned that it is another step to-
ward designing a perfect baby.  Richard
Nicholson, editor of the Bulletin of Medical
Ethics, said that, it is important to realize
that the same technique has be used to
screen out other abnormalities like Downs
and Turners syndrome.  Until now, fer-
tility specialists in the UK have only been
permitted to screen for specific genetic dis-
orders.  However, aneuploidy screening
can detect a whole range of genetic abnor-
malities, leading some to worry about in-
NORD ISSUES GENE PATENTING
STATEMENT
In May 2001, the National Organization
for Rare Disorders (NORD) issued a state-
ment condemning the U.S. Patent and
Trademark Offices (PTO) policy of allow-
ing scientists and corporations to patent
genes and gene sequences even before any
applications of this knowledge are known.
NORDs policy position regarding the pat-
enting of genes states that the practice re-
stricts scientific research, thereby limiting
the development of therapies and phar-
maceuticals that could benefit millions of
people. It argues that preventing research
on any illness, particularly those with a
genetic basis, is unethical.  The organi-
zation calls on PTO and the federal gov-
ernment to disallow future patenting of
genes or gene sequences.  According to the
statement, Congress should enact a com-
pulsory licensing law that requires free
access to genes by researchers without hav-
ing to pay fees or sign confidentiality
agreements.  Claiming that genes are not
inventions (and thus protected by PTO as
such), NORD calls for the federal govern-
ment to monitor current gene patent hold-
ers so that the latter could not require roy-
alty payments or secrecy agreements un-
less the gene or gene sequence has been
changed or engineered in order to create a
product for commercial use.  According to
NORD, until such time, free access to genes
should be mandated in order to foster re-
search.  The  full statement can be found at
http://www.rarediseases.org   *VG
IN THE SOCIETIES
rectives concerning the use of placebo con-
trol subjects in clinical research studies.
October 2000 revisions to the 1996 version
of the Declaration further restrict placebo
use in human research trials.  Some re-
searchers are calling for changes that might
alleviate the restrictions imposed in the
2000 revision.
While most changes done in October were
embraced by the research community, ex-
tensive controversy still surrounds Article
29.  This section declares, the benefits,
risks, burdens and effectiveness of a new
method should be tested against those of
the best current prophylactic, diagnostic,
and therapeutic methods.  This does not
exclude the use of placebo, or no treatment,
in studies where no proven prophylactic,
diagnostic or therapeutic method exists.
In other words, contrary to many national
research protocols, which allow the more
liberal use of placebo controls, the new
international directive restricts the use of
placebos in cases where a current treatment
might otherwise improve the health con-
dition of a study patient.
The Council for International Organiza-
tions of Medical Sciences (CIOMS) repre-
sents the views of researchers in opposi-
tion to the current version of the Declara-
tion of Helsinki.  CIOMS is a non-govern-
mental, international organization estab-
lished by the World Health Organization
(WHO) and the United Nations Educa-
tional, Scientific and Cultural Organiza-
tion (UNESCO) in 1949 to serve the scien-
tific interests of the international biomedi-
cal community.   They argue that with-
holding the best current treatment from
placebo control groups results in no seri-
ous adverse consequences.  Patients are
likely to experience only temporary dis-
comfort.  It is therefore implied that the
benefits of withholding short-term treat-
ment far outweigh the long-term risks to
the patient.
They go on to insist that the scientific and
ethical suitability of placebo-controlled
studies is expanded when patients are
switched to active treatments under cir-
cumstances where intolerable symptoms
continue. Further, researchers argue that
lack of a negative control, provided by an
untreated placebo group, will compromise
the scientific results of the trial.  No reli-
able data will be yielded in a comparison
of two treatments without such a control
group.
The Declaration of Helsinki is a widely
held international code of ethics, establish-
ing principles for medical research involv-
ing human subjects.  It has been revised
only five times since its initial adoption in
1964.   The current version can be found at
http://www.wma.net/.  If the workgroup
appointed by the WMA agrees on the need
for further modifications, the issue will be
addressed at the WMA assembly this fall.
*MD
discriminate screening that could elimi-
nate an embryo for what most would now
consider a minor genetic flaw.
No licenses for aneuploidy screening have
been issued yet.  Further information on
HFEA can be found on the WWW at: http:/
/www.hfea.gov.uk/.   *RJG
AMA ADOPTS NEW PRINCIPLES OF
MEDICAL ETHICS
For the first time in twenty-one years, the
American Medical Association (AMA)
adopted two new principles and revised
existing principles as a part of its Medical
Ethics. On June 17, 2001, the Revised Prin-
ciples of Medical Ethics were adopted.  The
action represents a change toward empha-
sizing patient care and providing access to
medical care for all people.
The most notable change to the document
is the addition of Principles VIII and IX.
